NICE technology appraisal guidance
Issued: November 2011
TA237

Ranibizumab for the treatment of diabetic macular oedema

This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta237

1 Guidance

1.1 Ranibizumab is not recommended for the treatment of visual impairment due to diabetic macular oedema.

1.2 People currently receiving ranibizumab for the treatment of visual impairment due to diabetic macular oedema should have the option to continue treatment until they and their clinicians consider it appropriate to stop.